MedTrace Logo

CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function

NCT02071602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-03-10

No results posted yet for this study

Summary

The primary endpoint is to assess the safety and tolerability of Cenderitide (CD-NP) with the incidence of symptomatic hypotension being one of the key safety variables.

Conditions

  • ST Elevation (STEMI) Myocardial Infarction of Anterior Wall

Interventions

DRUG

CD-NP

Randomized 1:1:1

Sponsors & Collaborators

Principal Investigators

  • Horng Chen, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-05-31
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02071602 on ClinicalTrials.gov